ACTA1 and Hepatic fibrosis: On the contrary, the administration of DHM (20, 40 mg/kg) effectively reduced the secretion of TGF-β1 and the expression of α-SMA, which intuitively indicated that DHM inhibited the activation of HSCs and thus reversed the development of liver fibrosis by TAA-induced.